Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Teva
Chinese Patent Office
Covington
Colorcon
US Department of Justice
Johnson and Johnson
Boehringer Ingelheim
Fuji
Cantor Fitzgerald

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,779,187

« Back to Dashboard

Which drugs does patent 8,779,187 protect, and when does it expire?

Patent 8,779,187 protects AMITIZA and is included in one NDA.

This patent has eighteen patent family members in fifteen countries.
Summary for Patent: 8,779,187
Title:Soft-gelatin capsule formulation
Abstract: The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved.
Inventor(s): Hashitera; Yukiko (Kobe, JP), Hirata; Ryu (Sanda, JP), Harada; Yasuhiro (Sanda, JP), Ueno; Ryuji (Potomac, MD)
Assignee: Sumcampo AG (Zug, CH) R-Tech Ueno, Ltd. (Tokyo, JP)
Application Number:13/679,005
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,779,187

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-002 Apr 29, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-001 Jan 31, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,779,187

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,026,393 Soft-gelatin capsule formulation ➤ Subscribe
8,338,639 Soft-gelatin capsule formulation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,779,187

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2637274 ➤ Subscribe
China 101410097 ➤ Subscribe
China 104983712 ➤ Subscribe
Denmark 1978944 ➤ Subscribe
European Patent Office 1978944 ➤ Subscribe
Spain 2392590 ➤ Subscribe
Israel 192867 ➤ Subscribe
Japan 2008534432 ➤ Subscribe
Japan 4783794 ➤ Subscribe
South Korea 20080090526 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Fish and Richardson
Daiichi Sankyo
AstraZeneca
Moodys
Cantor Fitzgerald
Cerilliant
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot